Plain-English Summary
SELECT is the major outcomes trial showing that semaglutide 2.4 mg reduced serious cardiovascular events in people with overweight or obesity who already had cardiovascular disease and did not have diabetes.
Key Findings
- Semaglutide reduced the risk of the composite major adverse cardiovascular event endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease without diabetes.
- The effect moved semaglutide beyond cosmetic weight-loss framing and into cardiometabolic outcomes in a high-risk population.
- The outcome population was specific: established cardiovascular disease, overweight or obesity, and no diabetes.
Limitations
- The results should not be generalized to lower-risk consumers without established cardiovascular disease.
- SELECT does not prove that every use of semaglutide for weight loss produces cardiovascular-event reduction.
- The trial evaluates semaglutide 2.4 mg with standard care, not compounded versions or unsupervised use.
Why It Matters
This is the strongest counter to the claim that GLP-1 drugs are only vanity weight-loss drugs, while still requiring careful population-specific framing.
Viral Vitalism Verdict
High-impact outcomes evidence, but only for the studied risk group. Use it to upgrade the GLP-1 narrative, not to overgeneralize cardioprotection to everyone.
Sources
- Semaglutide and cardiovascular outcomes in obesity without diabetes - New England Journal of Medicine
- SELECT trial: semaglutide and cardiovascular outcomes - PubMed